TY - JOUR
T1 - Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib
AU - Matrana, Marc R.
AU - Baiomy, Ali
AU - Campbell, Matthew
AU - Alamri, Suhail
AU - Shetty, Aditya
AU - Teegavarapu, Purnima
AU - Kalra, Sarathi
AU - Xiao, Lianchun
AU - Atkinson, Bradley
AU - Corn, Paul
AU - Jonasch, Eric
AU - Elsayes, Khaled M.
AU - Tannir, Nizar M.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Outcomes data in patients with metastatic non–clear-cell renal cell carcinoma (RCC) treated with pazopanib are limited. We identified 29 patients with non–clear-cell metastatic RCC who received pazopanib (9 in the front-line setting, and 20 in the salvage setting). Median overall survival was 31 months (95% confidence interval [CI], 9.2-NA [not available]) in the front-line group compared with 13.6 months (95% CI, 6.4-NA) in the salvage group. Background Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non–clear-cell RCC, but data on outcomes in this setting are limited. Patients and Methods We conducted a retrospective data analysis of records of consecutive metastatic non–clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan–Meier methods. Results Twenty-nine patients were identified with non–clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group. Conclusion Pazopanib showed efficacy in patients with metastatic non–clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non–clear-cell RCC in terms of efficacy and safety.
AB - Outcomes data in patients with metastatic non–clear-cell renal cell carcinoma (RCC) treated with pazopanib are limited. We identified 29 patients with non–clear-cell metastatic RCC who received pazopanib (9 in the front-line setting, and 20 in the salvage setting). Median overall survival was 31 months (95% confidence interval [CI], 9.2-NA [not available]) in the front-line group compared with 13.6 months (95% CI, 6.4-NA) in the salvage group. Background Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non–clear-cell RCC, but data on outcomes in this setting are limited. Patients and Methods We conducted a retrospective data analysis of records of consecutive metastatic non–clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan–Meier methods. Results Twenty-nine patients were identified with non–clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group. Conclusion Pazopanib showed efficacy in patients with metastatic non–clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non–clear-cell RCC in terms of efficacy and safety.
KW - Angiogenesis
KW - Kidney cancer
KW - Late relapse
KW - Targeted therapy
KW - Tyrosine-kinase inhibitor
KW - mTOR inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84994137873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994137873&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2016.07.016
DO - 10.1016/j.clgc.2016.07.016
M3 - Article
C2 - 27568124
AN - SCOPUS:84994137873
SN - 1558-7673
VL - 15
SP - e205-e208
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -